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M A J O R A R T I C L E
Influenza-Associated Mortality in Hong Kong
Chit-Ming Wong,1 King-Pan Chan,1 Anthony Johnson Hedley,1 and J. S. Malik Peiris2
Departments of 1Community Medicine and 2Microbiology, University of Hong Kong, Special Administrative Region of China
Background. The impact of influenza on mortality in countries in subtropical and tropical regions is poorly
quantified. Estimation of influenza-related illness in warm-climate regions is more difficult, because the seasonality
of virus circulation is less well-defined. Partly as a result of these factors, influenza vaccine is grossly underutilized
in the tropics, even for individuals 65 years of age.
Methods. Weekly numbers of deaths were modeled by Poisson regression, and excess deaths attributable to
influenza in Hong Kong were estimated for 1996–1999. Comparison of weekly mortality during periods of influenza
predominance and periods of low influenza activity was used to derive an alternative estimate of influenza-associated
mortality.
Results. Estimates derived from the Poisson model indicated that influenza resulted in 7.3 deaths per 100,000
population per year (95% confidence interval [CI], 3.1–11.4) from cardiorespiratory disease among individuals
aged 40–65 years and 102.0 deaths per 100,000 per population per year (95% CI, 61.2–142.7) among individuals
aged 65 years. Although respiratory diseases accounted for the majority of influenza-related deaths, influenza
also contributed to 13.8% (95% CI, 4.8%– 22.7%) and 5.3% (95% CI, 1.2%–9.3%) of deaths related to ischemic
heart disease.
Conclusion. Influenza is associated with deaths due to ischemic heart disease as well from respiratory diseases.
Overall influenza-associated mortality in a region with a warm climate, such as Hong Kong, is comparable with
that documented in temperate regions. The need for influenza vaccination in tropical regions needs to be reassessed.
Influenza is a vaccine-preventable disease that is as-
sociated with significant morbidity and mortality. There
is a need for reliable data on the influenza-associated
clinical disease burden on which national and global
policy decisions on influenza vaccine can be based [1].
The morbidity and mortality caused by influenza is
often attributed to secondary bacterial infection, and
the primary viral illness goes unrecognized [2]. A vi-
rological diagnosis of influenza is often not sought, and
even when it is, influenza viruses may no longer be
detectable after secondary bacterial infection has su-
pervened [3, 4]. It is now recognized that influenza
contributes to excess morbidity for conditions not pre-
viously thought to be associated with infection, such
as congestive heart failure [5].
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Statistical models have been used to predict season-
ally adjusted baseline trends in mortality, with the as-
sumption that the number of deaths that exceed the
expected baseline number during an influenza epidemic
is related to influenza [6, 7]. However, the reliable es-
timation of disease burden is dependent on a well-
defined population denominator. The assumption—in
studies based on nationwide data—that influenza ac-
tivity is uniform in the area under study may not be
valid [8]. Furthermore, it is also recognized that re-
spiratory syncytial virus (RSV) can contribute to disease
morbidity in adults and older persons, with clinical
syndromes very similar to those of influenza [2, 9, 10].
Because the seasonality of infection due to influenza
virus and to RSV often overlaps in temperate regions,
it is difficult to differentiate the contribution of these
2 viruses to excess mortality.
Although estimates of the influenza disease burden
are available for temperate regions of the developed
world [2, 11, 12], there are no valid estimates for trop-
ical and subtropical regions [13]. There are several rea-
sons for the lack of information from the tropics. Virus
circulation tends to be less seasonal and, in some re-
gions, may continue year-round [14]. The focused win-
ter seasonality of influenza in temperate regions makes
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the impact of influenza obvious (e.g., through the increased
demand for hospitalization). On the other hand, the more dif-
fuse seasonality of virus activity in the tropics results in the
clinical impact of the disease being less obvious, leading to the
perception that influenza is a less important cause of serious
illness and mortality. The lack of well-defined data on the sea-
sonality of influenza also makes it more difficult to apply com-
monly used models for estimating the excess influenza-associ-
ated disease [13].
Hong Kong, with a latitude of 2145′ North and mean tem-
perature of 24C, is geographically situated in the tropics and
has a subtropical climate. It lies in the region considered to be
the hypothetical epicenter for the emergence of influenza pan-
demics [15]. However, apart from the recent outbreaks of avian
influenza [16], influenza is not currently recognized as a major
health problem in Hong Kong. Recent studies, based on clinical
case definitions of “influenza-like illness,” failed to document
significant influenza-associated morbidity and mortality [17,
18]. However, without virological validation, such clinical case
definitions are often poor indicators of influenza when applied
outside periods of peak influenza activity [19], particularly in
the context of year-round influenza circulation. In this study,




Weekly numbers of deaths over a 4-year period (1996–1999)
were obtained from the Hong Kong Census and Statistics De-
partment for 4 underlying causes of death—cardiovascular and
respiratory (cardiorespiratory) disease (International Classifi-
cation of Diseases, Ninth Revision [ICD-9], codes 390–519),
pneumonia and influenza (ICD-9 codes 480–487), chronic ob-
structive pulmonary disease (COPD) (ICD-9 codes 490–496),
and ischemic heart disease (IHD) (ICD-9 codes 410–414)—as
well as for all-cause death [20]. Weekly records of mean tem-
perature and relative humidity were derived from the Hong
Kong Observatory [21]. Weekly numbers of positive isolations
of influenza A and influenza B (hereafter, “influenza”) virus
and RSV, as well as the total number of specimens tested, were
obtained from the Department of Microbiology, Queen Mary
Hospital (Hong Kong). The laboratory in this department re-
ceives 6000–7000 clinical specimens annually.
Statistical Analysis
Comparison between influenza predominance and baseline
periods. We defined influenza predominance as the period of
2 consecutive weeks in which the weekly isolation of influenza
virus accounted for at least 4% (i.e., twice the weekly average)
of the annual total number of influenza virus isolations and
!2% of the annual total number of RSV isolations. Baseline
was defined as the period of 2 consecutive weeks during
which both influenza virus and RSV weekly isolations were
!2% of the annual total number of isolations of each virus
[22]. The remaining weeks in each study year were classified
as intermediate periods. We estimated excess deaths by taking
the difference in number of deaths per week between the in-
fluenza predominance and baseline periods and multiplying the
result by the total number of predominance weeks [22]. The
possible confounding effect of RSV on influenza virus–associ-
ated mortality was minimized by restricting the analysis to
weeks in which diagnosis of RSV infection was !2% of the
annual total of RSV isolations.
Poisson regression modeling. We applied Poisson regression
[23, 24] to the weekly number of each of the health outcomes
under study, including as covariates weekly mean temperature
and relative humidity, as well as 4 separate dummy variables for
the years 1996–1999 and 2 pairs of seasonality variables. For
additional control of seasonal variation in the amplitude of deaths
in each year, we defined the year-by-seasonality variables as the
multiplicative product of the dummy variable for each year and
the 2 pairs of seasonality variables. These year-by-seasonality var-
iables were then entered into the model.
The proportions of laboratory specimens that tested positive
for influenza virus and RSV each week were entered into the
model to assess the impact of influenza virus, with adjustment
for RSV. The delayed impact (i.e., lag effect) of influenza vi-
rus and RSV on outcome was assessed by adding the virolog-
ical data from 0–3 weeks preceding the deaths into the model.
For each virus and outcome, we selected as the best lag effect
the one with the most significant association with mortality.
The difference between the total number of observed deaths
and the total number of expected deaths (when the proportion
of specimens that tested positive for influenza or RSV in the
model was set to 0), divided by the total number of observed
deaths, yielded the fraction of deaths associated with influenza
[25]. The excess number of deaths attributable to influenza was
estimated by multiplying the total number of deaths by the
influenza-associated fraction of deaths. The statistical package
Splus (StatSci) was used for analysis [26]. Detailed data and
results statistical analysis are available as supplementary infor-
mation from the authors.
RESULTS
In the categories studied, the group aged 65 years contribut-
ed ∼70% to 90% of all deaths. Over the 4-year study period,
all outcomes under study were relatively constant, except that
deaths due to pneumonia and influenza showed a decreasing
trend (data not shown). Influenza virus activity during the
period under study is shown in figure 1.
In a comparison of weekly mortality between the influenza
predominance and baseline periods, we estimated that ∼1% to
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Figure 1. Weekly number of influenza-associated death per 4 causes, observed and fitted according to the core model (with control for seasonal
patterns), and the proportion of influenza-positive isolates used in laboratory diagnosis for the all-ages group.
8% of the health outcomes under study were due to influenza.
During the 4-year period, ∼2400 deaths due to cardiorespira-
tory conditions and ∼500 deaths due to IHD in the all ages
group were attributable to influenza (table 1). RSV activity and
the concentrations of air pollutants during these 2 periods were
comparable (data not shown). During periods of influenza pre-
dominance, the mean temperature was lower (18C vs. 22C)
and the relative humidity was higher (78% vs. 73%) than dur-
ing the baseline period. Because there were no definable weeks
of influenza predominance in 1997, there are no estimates of
influenza-associated excess mortality for this year.
The weekly time series plots of mortality in the all-ages group
show that each of the 4 health outcomes had 1 main cycle and
2 subcycles each year, a pattern similar to that seen with in-
fluenza activity (figure 1). The Poisson model fitted the data
adequately, as indicated by the absence of any discernible pat-
terns and by auto-correlation (i.e., correlation between suc-
cessive measurements) in the residuals (supplementary data are
available from the authors). For all health outcomes in the
group aged 65 years and the all ages group, there were sig-
nificant associations with influenza, with the maximum effect
seen at a best lag of 2 weeks for death due to cardiorespiratory
conditions, pneumonia and influenza, and COPD and a best
lag of 1 week for all-cause and IHD-attributed death. For all
health outcomes in the group aged 40–64 years, the best lag
effects were shown at a longer lag period of 2–3 weeks. No
significant association between RSV infection and mortality was
seen for any lag periods between 0–3 weeks (except for mor-
tality attributable to pneumonia and influenza in the group
aged 65 years), and no lag period was assumed for RSV
infection (data not shown).
The weekly proportions of laboratory-based virological di-
agnoses of influenza showed a significant association with all
health outcomes under study, except for death due to pneu-
monia and influenza in the group aged 40–64 years, which only
accounted for 7% of all deaths attributed to this diagnosis. The
proportion of influenza-associated deaths throughout the study
period was 3%–16%. Over the 4-year period under study, ∼800
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Table 1. Excess deaths during influenza predominance periods over baseline periods during 1996–1999.
Characteristic
Study year No. of excess deaths
1996 1997a 1998 1999 Per year
Per 100,000 population
per year (95% CI)b
No. of predominance weeks (n p 19) 5 0 7 7 … …
No. of baseline weeks (n p 78) 25 24 16 13 … …
No. of excess deaths per age group, by cause
All cause
40–64 years 53 0 46 89 47 2.4 (1.0–3.9)
65 years 603 0 816 1137 639 93.2 (78.4–107.7)
All agesc 650 0 897 1233 695 10.6 (8.9–12.3)
Cardiorespiratory disease
(ICD-9 codes 390–519)
40–64 years 77 0 63 121 65 3.4 (2.5–4.3)
65 years 492 0 685 963 535 78.1 (67.2–89.0)
All agesc 568 0 759 1090 604 9.2 (8.0–10.5)
Pneumonia and influenza
(ICD-9 codes 480–487)
40–64 years 12 0 0 17 7 0.4 (0.0–0.7)
65 years 126 0 25 308 115 16.7 (9.8–23.7)
All agesc 138 0 29 335 126 1.9 (1.1–2.7)
Chronic obstructive pulmonary disease
(ICD-9 codes 490–496)
40–64 years 11 0 18 37 16 0.8 (0.6–1.1)
65 years 119 0 122 258 125 18.2 (13.8–22.7)
All agesc 129 0 140 293 140 2.1 (1.6–2.7)
Ischemic heart disease
(ICD-9 codes 410–414)
40–64 years 19 0 19 30 17 0.9 (0.4–1.3)
65 years 93 0 207 168 117 17.1 (12.8–21.3)
All agesc 113 0 230 196 135 2.1 (1.6–2.5)
NOTE. The annual number of excess deaths is obtained by multiplying the difference in the observed weekly number of deaths
between periods of influenza predominance and at baseline by the number of weeks of influenza predominance. ICD-9, International
Classification of Diseases, Ninth Revision.
a The number of influenza-associated excess deaths for 1997 could not be estimated because of substantial cocirculation of influenza
virus and respiratory syncytial virus during this period, which precluded the identification of periods of influenza predominance.
b Calculation based on population in corresponding age groups
c The number of excess deaths was estimated from a model developed according to data for each age group and was independent
of those for the other age groups. As a result, the number of excess deaths in the all-ages group is not a total sum of excess deaths
for each of the age groups.
annual deaths due to cardiorespiratory conditions and ∼200
annual deaths due to IHD in the all ages group were attributable
to influenza (table 2).
The excess deaths at lag 0 for the group aged 65 years and
for the all ages group were, in general, lower than those esti-
mated at the best lag week, but the effects were statistically
significant ( ) for all mortality outcomes, except for deathP ! .05
due to pneumonia and influenza. But for the group aged 40–
64 years, only death from cardiorespiratory diseases and from
IHD showed a significant effect at lag 0 (data not shown).
DISCUSSION
Previous estimations, using statistical models, of morbidity and
mortality attributable to influenza have been criticized on the
grounds that winter baseline periods may not be free of influ-
enza activity [8] and because other viruses (such as RSV) that
are known to contribute to respiratory mortality among older
adults may confound these estimates [2]. Recent studies have
addressed this problem by comparing periods of influenza pre-
dominance with periods during which neither influenza virus
nor RSV circulated, to avoid the confounding effect of RSV
infection on hospitalization [22, 27, 28]. Alternatively, regres-
sion modeling of the number of deaths associated with pneu-
monia and influenza has taken into account both influenza
virus and RSV [2, 7, 29]. We used both of these approaches in
parallel to estimate influenza-related excess mortality in Hong
Kong, with broadly comparable results indicating that, each
year, influenza was responsible for ∼78.1 to 102.0 excess deaths
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Table 2. Influenza-associated excess deaths in 1996–1999 estimated by Poisson modeling after adjustment for co-
variates, including respiratory syncytial virus infection (1996–1999).







No. of excess deaths
per year (95% CI)
No. of excess deaths
per 100,000 population
per year (95% CI)b
All cause
40–64 years 3 3.4 (1.1–5.8) 227 (73–387) 11.8 (3.8–20.1)
65 years 1 3.9 (2.4–5.4) 933 (574–1291) 136.1 (83.7–188.4)
All agesc 1 3.3 (1.9–4.7) 1073 (618–1528) 16.4 (9.4–23.3)
Cardiorespiratory conditions
(ICD-9 codes 390–519)
40–64 years 2 7.7 (3.3–12.0) 140 (60–219) 7.3 (3.1–11.4)
65 years 2 5.5 (3.3–7.7) 699 (419–978) 102.0 (61.2–142.7)
All agesc 2 5.5 (3.4–7.6) 813 (503–1124) 12.4 (7.7–17.1)
Pneumonia and influenza
(ICD-9 codes 480–487)
40–64 years 0 5.9 (6.8 to 18.6) 16 (19 to 51) 0.8 (1.0 to 2.6)
65 years 2 8.1 (4.4–11.8) 270 (146–393) 39.3 (21.4–57.3)
All agesc 2 7.4 (3.7–11.1) 272 (136–408) 4.1 (2.1–6.2)
Chronic obstructive pulmonary disease
(ICD-9 codes 490–496)
40–64 years 2 15.9 (2.5–29.1) 33 (5–61) 1.7 (0.3–3.2)
65 years 2 8.7 (4.1–13.4) 169 (79–260) 24.6 (11.6–37.9)
All agesc 2 9.4 (4.8–13.9) 204 (104–301) 3.1 (1.6–4.6)
Ischemic heart disease
(ICD-9 codes 410–414)
40–64 years 2 13.8 (4.8–22.7) 63 (22–104) 3.3 (1.1–5.4)
65 years 1 5.3 (1.2–9.3) 147 (33–259) 21.5 (4.9–37.7)
All agesc 1 6.1 (2.4–9.8) 200 (79–321) 3.0 (1.2–4.9)
NOTE. ICD-9, International Classification of Diseases, Ninth Revision.
a Estimated by taking total observed number minus the total expected number (when influenza proportions are set to 0 in the Poisson
regression model) and dividing by the total observed number expressed as a percentage.
b Based on population in corresponding age groups.
c The number of excess deaths was estimated from a model developed according to data for each age group and was independent of those
for the other age groups. As a result, the number of excess deaths in the all-ages group is not a total sum of excess deaths for each of the
age groups.
due to cardiorespiratory conditions and for 17.1 to 21.5 excess
deaths due to IHD per 100,000 population aged 65 years.
The age-specific influenza-attributable mortality rates de-
rived by Poisson regression were higher than influenza-
associated death derived from the comparison of baseline and
predominance periods. Rates derived from the latter will un-
derestimate the impact of influenza in those years in which
there is substantial cocirculation of influenza virus and RSV,
which precludes the identification of periods of influenza pre-
dominance that are free of RSV. In our study, this happened
in 1997, and this analysis clearly fails to estimate influenza-
associated mortality during this year.
Another potential criticism of the method of comparison of
baseline and influenza predominance periods is that the periods
being compared may differ because of seasonal and other fac-
tors that may contribute to mortality. Both baseline and influ-
enza predominance periods occurred in the cool season, when
levels of air pollutants are higher, but there was no difference
between the periods with respect to the mean levels of all 4
pollutants (e.g., nitrogen dioxide, sulphur dioxide, respirable
particulates, and ozone) (data not shown).
The alternative method of Poisson modeling allows adjust-
ment for the impact of seasonal and climatological factors and
also allows the impact of influenza to be estimated, with ad-
justment for potential confounding factors. In our study, the
weekly variation of each mortality outcome was modeled with
the seasonal amplitude specific to each year of the study, with
adjustment for temperature, humidity, and RSV activity. Influ-
enza was significantly associated with mortality in each of the
health outcomes studied, with the exception of the smaller
number of deaths due to pneumonia and influenza in the group
aged 40–64 years, in which the wider 95% CIs precluded dem-
onstration of a significant effect.
The Poisson regression estimates of influenza-associatedpneu-
monia and influenza-associated mortality per 100,000 popu-
lation per year in Hong Kong were 39.3 for the group aged
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65 years and 4.1 for the all-ages group, which are similar to
the figures of 22.1 and 3.1 per 100,000 population per year,
respectively, estimated by this method in the United States [23].
Influenza-associated mortality in the United States for all re-
spiratory and circulatory deaths per 100,000 population per
year in the group aged 65 years was 98.3 and in the all-ages
group was 13.8, which is closely comparable to the rates of
102.0 and 12.4 per 100,000 population per year, respectively,
we obtained for Hong Kong. In the United States, the greatest
number of influenza-associated deaths was associated, in de-
scending order, with influenza A subtype H3N2, followed by
influenza B and influenza A subtype H1N1 [23, 29]. In Hong
Kong, during the 4-year period we studied, subtype H3N2 vi-
ruses accounted for 77% (range, 65%–94%) of all influenza
viruses isolated (data not shown). Both the causes and mag-
nitude of influenza-associated mortality are similar in Hong
Kong and the United States, especially in the group aged 65
years, for whom vaccination is strongly recommended.
There is little additional data on influenza-associated mor-
tality in the tropics or subtropics [13]. One study from Sin-
gapore estimated that ∼265 such deaths per 100,000 population
65 years of age occur annually. However, this estimate was
derived from the total number of deaths that were coded “pneu-
monia and influenza,” based on the assumption that 40% of
these deaths were associated with influenza [30].
Interestingly, both the Poisson analysis (table 2) and the
comparison of periods of influenza predominance with baseline
periods (table 1) reveal a significant association between IHD-
attributed death and influenza. Poisson analysis indicates that
influenza was associated with 13.8% and 5.3% of IHD-attrib-
uted deaths in the groups aged 40–64 and 65 years, respec-
tively (table 2). The influenza-associated excess IHD-attributed
mortality in the group aged 65 years was 21.5 deaths per
100,000 population per year and accounted for a significant
component of the overall mortality associated with influenza.
In our analyses, influenza was associated with 4%–6% of all
deaths from IHD annually.
There is accumulating evidence suggesting that influenza
plays a role in triggering IHD. Much of these data come from
studies showing that influenza vaccine exerts a protective ef-
fect against IHD during hospitalization or against recurrences
of IHD [31–34], although other studies have failed to dem-
onstrate such an association [35]. Influenza and other acute
infections may predispose to increased risk of IHD through
alterations in circulating clotting factors, platelet aggregation
and lysis and through alterations in concentrations of inflam-
matory-response proteins and cytokines [36]. In a mouse
model, it was found that influenza infection promotes in-
flammation, smooth muscle cell proliferation, and fibrin de-
position in atherosclerotic plaques [37]. Our conclusions,
which are based on weekly data on mortality and influenza
virus activity, show that influenza is significantly associated
with IHD-attributed mortality and supports the concept that
IHD is, in part, a vaccine-preventable disease.
Meta-analysis of the efficacy of influenza vaccine in older
persons indicates that it reduces influenza-like illness by 35%,
hospitalization due to pneumonia and influenza by 47%, and
all-cause mortality by 50% [35]. However, worldwide, influ-
enza vaccine is grossly underutilized, particularly in tropical
and subtropical regions, in part because its clinical impact is
not recognized [13] and influenza is perceived to be a less
important disease in warmer climates [17, 18]. Thus, influ-
enza vaccination is not accorded high priority, even for in-
dividuals aged 65 years [36]. Our findings suggest that this
perception is incorrect and indicate that vaccination, espe-
cially for individuals 165 years of age, is as relevant in warm
climates as it is in temperate regions.
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